NovaBridge Biosciences (NBP) Other financing activities (2020 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Other financing activities of $1.2 million for Q4 2025, up 220.7% on a QoQ basis from -$966000.0 in Q3 2025.
NovaBridge Biosciences (NBP) Other financing activities (2020 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Other financing activities for 2 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.
- Quarterly Other financing activities changed N/A year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $200000.0 (changed N/A YoY) and the FY2025 annual result came in at $200000.0, up 104.8% from the prior year.
- Other financing activities rose to $1.2 million in Q4 2025 per NBP's latest filing, from -$966000.0 in the prior quarter.
- Over the last five years, Other financing activities for NBP reached as high as $1.2 million in Q4 2025 and fell as low as -$966000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | NovaBridge Biosciences | 397.57 Mn | 397.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.17 Mn |
| Dec 31, 2025 | 1.17 Mn |
| Sep 30, 2025 | -966,000.00 |
| Sep 30, 2025 | -966,000.00 |
| Dec 31, 2020 | 420.83 Mn |
| Dec 31, 2020 | 420.83 Mn |